| name | target-validation |
| description | Comprehensive target validation assessing druggability, disease association strength,
tractability, and competitive landscape. Use for go/no-go decisions on target selection.
Keywords: target validation, druggability, tractability, disease association, genetic validation
|
| category | Target Analysis |
| tags | ["target","validation","druggability","tractability","genetics"] |
| version | 1.0.0 |
| author | Drug Discovery Team |
| dependencies | ["opentargets","gwas-catalog","clinvar","uniprot"] |
Target Validation Skill
Comprehensive target validation for drug discovery decision-making.
Quick Start
/target-validate EGFR --full
/validate "KRAS G12C" --association oncology
/tractability --target "BCR-ABL" --include genetic,chemical,clinical
Validation Framework
The 4-Pillar Framework
1. Genetic Validation
├── GWAS associations
├── Mendelian randomization
├── CRISPR screens
└── Animal models
2. Chemical Validation
├── Known binders
├── Tool compounds
├── Co-crystal structures
└── SAR coverage
3. Clinical Validation
├── Approved drugs
├── Pipeline drugs
├── Genetic therapies
└── Biomarker linkage
4. Competitive Landscape
├── Active companies
├── Patent density
├── Differentiation potential
└── Market maturity
Output Structure
# Target Validation: EGFR
## Validation Summary
| Pillar | Score | Status |
|--------|-------|--------|
| Genetic | 5/5 | ✓ Strong |
| Chemical | 5/5 | ✓ Strong |
| Clinical | 5/5 | ✓ Strong |
| Competition | 2/5 | ⚠ Crowded |
**Overall Validation**: Strong (17/20)
## Genetic Validation
### Human Genetics
| Evidence | Score | Details |
|----------|-------|---------|
| GWAS | 5/5 | 5 genome-wide significant associations |
| Mendelian | 5/5 | Activating mutations cause lung cancer |
| Somatic | 5/5 | Mutations in 15% NSCLC |
| eQTL | 4/5 | Strong expression QTLs |
| PheWAS | 3/5 | Cancer-associated phenotypes |
**Key Studies**:
- Zhang et al. (2020): OR = 2.5, p = 2×10⁻¹²
- Mendelian randomization supports causality
### Animal Models
| Model | Evidence | Phenotype |
|-------|----------|----------|
| Knockout mouse | 5/5 | Lung development defects |
| Transgenic (mutant) | 5/5 | Tumor formation |
| Zebrafish | 3/5 | Developmental phenotype |
## Chemical Validation
### Known Binders
| Compound | Type | Potency | Status |
|----------|------|---------|--------|
| Erlotinib | Small molecule | 2 nM | Approved |
| Osimertinib | Small molecule | 1 nM | Approved |
| Cetuximab | Biologic | 0.1 nM | Approved |
| Amivantamab | Biologic | 0.5 nM | Phase 3 |
### Structural Coverage
| Metric | Value |
|--------|-------|
| PDB entries | 127 |
| Co-crystals | 89 |
| Active conformations | 45 |
| Inactive conformations | 12 |
**Conclusion**: Excellent structural coverage for SBDD
## Clinical Validation
### Approved Drugs
| Drug | Indication | Year | Sales |
|------|-----------|------|-------|
| Erlotinib | NSCLC | 2004 | $1.5B |
| Gefitinib | NSCLC | 2002 | $0.8B |
| Osimertinib | NSCLC | 2015 | $5.2B |
| Afatinib | NSCLC | 2013 | $0.3B |
### Pipeline Drugs
| Drug | Company | Phase | Indication |
|------|---------|-------|------------|
| Lazertinib | J&J | 3 | NSCLC |
| Nazartinib | Novartis | 2 | NSCLC |
**Clinical Confidence**: Proven mechanism with multiple approvals
## Competitive Landscape
### Active Companies (2024)
| Company | Phase | Assets |
|---------|-------|--------|
| AstraZeneca | 3 | 3rd-gen TKI |
| Johnson & Johnson | 3 | 4th-gen TKI |
| Roche | 2 | Biologics |
| Merck | 1 | ADC |
| BeiGene | 2 | TKI |
| Metric | Value |
|--------|-------|
| Active patents | 245 |
| Key patents expiring | 2030-2035 |
| White space | 4th-gen, combinations |
: High competition but proven market
| Metric | Score | Details |
|--------|-------|---------|
| Class | A | Kinase, well-characterized |
| Binding site | A | ATP pocket, drug-like |
| Location | A | Cell surface (TKI) |
| Assayability | A | Biochemical, cellular |
| Selectivity | B | Kinome-wide selectivity needed |
: Highly tractable (class A kinase)
| Risk | Level | Mitigation |
|------|-------|-----------|
| Safety | Medium | Cardiac toxicity monitoring |
| Resistance | High | 3rd/4th-gen solutions |
| Competition | High | Differentiate on resistance |
| IP | Medium | Novel chemical series |
: GO - Proceed with EGFR program
:
Strong genetic validation
Proven clinical mechanism
Tractable target
Large market despite competition
:
Focus on resistance mutations (C797S)
Combination approaches
CNS-penetrant molecules
:
Review 4th-gen competitive landscape
Assess CNS penetration opportunity
Evaluate combination strategies
Validation Scoring
Genetic Evidence (0-5)
| Score | Criteria |
|---|
| 5 | Definitive causal link (Mendelian) |
| 4 | Strong GWAS + functional validation |
| 3 | GWAS association only |
| 2 | Moderate association |
| 1 | Weak genetic evidence |
| 0 | No genetic evidence |
Chemical Evidence (0-5)
| Score | Criteria |
|---|
| 5 | Multiple drug classes, many binders |
| 4 | Several binders, good SAR |
| 3 | Some binders, limited SAR |
| 2 | Few tool compounds |
| 1 | Probes only |
| 0 | No chemical matter |
Clinical Evidence (0-5)
| Score | Criteria |
|---|
| 5 | Multiple approved drugs |
| 4 | One approved, others in pipeline |
| 3 | Late-stage pipeline |
| 2 | Early clinical evidence |
| 1 | Preclinical only |
| 0 | No clinical evidence |
Running Scripts
python scripts/target_validation.py EGFR --full
python scripts/target_validation.py KRAS --association oncology
python scripts/tractability.py --target "BCR-ABL" --structure
python scripts/target_validation.py EGFR KRAS ALK --compare
Requirements
pip install requests pandas numpy
pip install scipy statsmodels
Reference
Best Practices
- Use multiple evidence types: No single source sufficient
- Weight clinical highest: Approved drugs = strongest validation
- Consider disease: Oncology targets different from CNS
- Assess timing: Early targets = higher risk/reward
- Review competition: Impacts differentiation strategy
Common Pitfalls
| Pitfall | Solution |
|---|
| Over-reliance on expression | Functional validation needed |
| Ignoring genetics | Human genetics predicts clinical success |
| Late to crowded targets | Early differentiation key |
| Undervaluing safety | Safety failures expensive |
| Single-source bias | Triangulate evidence |
